Team

Fathia obtained a PhD in immunology from the Pasteur Institute in Paris in 1984. After a 3-year post-doctoral training at NIH, Bethesda, USA, she was recruited to INSERM to continue her research at Gustave Roussy Institute.
During her career, she was initially interested by murine B lymphocytes and then human T lymphocytes and their receptors. Since 1996, she has directed her research toward tumor immunology and immunotherapy.
She has contributed to the identification of tumor-associated antigens in lung cancer that are recognized by cytotoxic T lymphocytes (CTL) and has helped elucidating the mechanisms involved in optimizing the anti-tumor CTL response.

Cédric , President & CEO, who will design the drug candidate's development strategy based on regulatory requirements and key administrative functions. Cédric, who is qualified as a chartered accountant, will bring his expertise in management and pharmaceutical development to the project

Jean-Luc  is Professor of Hematology at the University of Nantes in France. He has been Chairman of the French National Authority for Health (HAS) from February 2011 to January 2016 and Chair of its Economic and Public Health Evaluation Committee from February 2014 to January 2016. He headed the Department of Clinical Haematology in Nantes University Hospital for 24 years and was Director of the Cancer Center René Gauducheau in Nantes from October 2008 to January 2011. Prof. Harousseau has also been a member of the Scientific Advisory Board of the French National Cancer Institute and President of the Clinical Research in National Oncology Committee from October 2008 to January 2011. He joined Elyssamed in September 2017 as a Chief Medical Officer (CMO) and a Board Member.